Lifecycle dominates the volatilome character of the dimorphic fungus *Coccidioides* spp.

Emily A. Higgins Keppler[a,b], Heather L. Mead[c], Bridget M. Barker[c], Heather D. Bean[a,b]#

[a]School of Life Sciences, Arizona State University, Tempe, AZ, United States

[b]Center for Fundamental and Applied Microbiomics, The Biodesign Institute, Arizona State

University, Tempe, AZ, United States

[c]Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, AZ, United States

Running Title: Lifecycle dominates the volatilome of *Coccidioides*

#Address correspondence to Heather D. Bean, Heather.D.Bean@asu.edu

Abstract word count = 204

Text word count = 4039

ABSTRACT

Valley fever (coccidioidomycosis) is an endemic fungal pneumonia of the North and South American deserts. The causative agents of Valley fever are the dimorphic fungi *Coccidioides immitis* and *C. posadasii*, which grow as mycelia in the environment and spherules within the lungs of vulnerable hosts. The current diagnostics for Valley fever are severely lacking due to poor sensitivity and invasiveness, contributing to a 23-day median time-to-diagnosis, and therefore new diagnostic tools are needed. We are working toward the development of a breath-based diagnostic for coccidioidomycosis, and in this initial study we characterized the volatile metabolomes (or volatilomes) of *in vitro* cultures of *Coccidioides*. Using solid-phase microextraction and comprehensive two-dimensional gas chromatography coupled to time-of-flight mass spectrometry (GC×GC–TOFMS), we characterized the VOCs produced by six strains of each species during mycelial or spherule growth. We detected a total of 353 VOCs that were at least two-fold more abundant in a *Coccidioides* culture versus medium controls and found the volatile metabolome of *Coccidioides* is more dependent on growth phase (spherule versus mycelia) than on the species. The volatile profiles of *C. immitis* and *C. posadasii* have strong similarities, indicating that a single suite of Valley fever breath biomarkers can be developed to detect both species.

IMPORTANCE

Coccidioidomycosis, or Valley fever, causes up to 30% of community-acquired pneumonias in endemic and highly populated areas of the US desert southwest. The infection is difficult to diagnose by standard serological and histopathological methods, which delays an appropriate treatment. Therefore, we are working toward the development of breath-based diagnostics for

Valley fever. In this study, we characterized the volatile metabolomes of six strains each of *Coccidioides immitis* and *C. posadasii*, the dimorphic fungal species that cause Valley fever. By analyzing the volatilomes during the two modes of growth for the fungus—mycelia and spherules—we observed that the lifecycle plays a significant role in the volatiles produced by *Coccidioides*. In contrast, we observed no significant differences in the *C. immitis* versus *C. posadasii* volatilomes. These data suggest that lifecycle, rather than species, should guide the selection of putative biomarkers for a Valley fever breath test.

INTRODUCTION

Coccidioidomycosis, or Valley fever, is a disease that is endemic to the deserts of the western United States, Mexico, and Central and South America and is responsible for an estimated 350,000 new infections per year (1). In endemic and highly populated areas of the US, e.g., Phoenix and Tucson, Arizona and the San Joaquin Valley in California, up to 30% of community-acquired pneumonias may be caused by Valley fever, and with growing populations in these regions, Valley fever cases in the US are expected to climb (2). The causative agent of Valley fever is the opportunistic pathogen *Coccidioides*, a genus of dimorphic fungus comprised of two species, *Coccidioides immitis* and *C. posadasii*. In the environment, *Coccidioides* spp. grow in the soil during rainy periods as mycelia, which become dormant and form arthroconidia during dry periods. As the soil is disturbed, the arthroconidia can become airborne, and when inhaled, the fungus can initiate a parasitic lifecycle as spherules within the lungs of a susceptible host, causing pneumonia. The median duration of human Valley fever pneumonia is 120 days, costing $93,734 per person in direct and indirect costs (2, 3). Approximately three quarters of the

diagnosed cases of Valley fever require antifungal therapy (4), and 1% of those infected will

experience disseminated disease, with a third of those being fatal (4).

A definitive diagnosis for Valley fever requires a positive fungal culture or histological

examination of tissue or bodily fluid. However, due to the invasiveness of obtaining suitable lung

specimens for culture or histology, serological testing for antibodies against *Coccidioides* is the

most commonly performed diagnostic test. Multiple serological tests are available for IgM, IgG,

or complement-fixing antibodies, as well as an enzyme-linked immunoassay that uses

proprietary coccidioidal antigens. However, these tests lack sensitivity for coccidioidomycosis

(5, 6). Due to the difficulty in diagnosing Valley fever, it is often mistaken for bacterial

pneumonia and inappropriately treated with antibiotics (7-10). The lack of a suitable diagnostic

strongly contributes to an unacceptably long 23-day median time-to-diagnosis (2).

Breath-based diagnostics are a promising novel approach for diagnosing respiratory infections.

Numerous *in vitro* studies have demonstrated that bacterial and fungal respiratory pathogens

have unique volatile metabolome (or *volatilome*) signatures that can be used to differentiate and

identify them to the genus, species, and strain level (11). Thus far, relatively few studies have

specifically focused on identifying breath biomarkers for fungal lung diseases. *In vitro* analyses

of the volatiles produced by *Aspergillus* spp. have shown that fungi produce many compounds

that are also frequently detected in bacterial cultures, e.g., (alcohols) ethanol, propanol, (ketones)

acetone, 2-nonanone, 2-undecanone, 2,3-butanedione, (sulfides) dimethyl disulfide, dimethyl

trisulfide, and (pyrazines) 2-methyl pyrazine, and 2,5-dimethyl pyrazine (12-16). However,

Aspergillus also produces a wider variety of monoterpenes, sesquiterpenes, and terpenoids,

which are less common in bacterial volatilomes (14, 17). With this knowledge, Koo et al. used a

biologically guided approach to identify volatile biomarkers of pulmonary invasive aspergillosis

(IA), focusing on terpenes and terpenoids produced *in vitro* as putative biomarkers for a breath

test (17). They determined that the *A. fumigatus in vitro* volatilome contained a distinctive

combination of monoterpenes and sesquiterpenes, and in breath the sesquiterpenes were the most

specific for differentiating patients with IA versus other pulmonary infections (17). This example

for *A. fumigatus* establishes a proof-of-concept that direct detection of fungal metabolites in

breath can be used as a noninvasive, species-specific approach to identify the underlying

microbial cause of pneumonia.

We are taking an *in vitro*-guided approach toward developing a Valley fever breath test by first

building a catalog of volatile compounds produced by *C. immitis* and *C. posadasii*. In this study,

we have cultured six strains of each species and used solid-phase microextraction and

comprehensive two-dimensional gas chromatography – time-of-flight mass spectrometry

(GC×GC–TOFMS) to characterize the volatile organic compounds (VOCs) produced during

mycelial or spherule growth. We expected to find significant differences in the VOCs between

species and between lifecycles, but also posited that there would be a subset of VOCs that are

common to *Coccidioides* spp. during spherule growth, which will serve as our candidate

biomarkers for breath test development.

RESULTS

***Coccidioides* isolates in this study**

The *Coccidioides* genus is widely distributed throughout North and South America. The genus is

composed of two geographically (18) and genetically distinct species (18, 19), *C. posadasii* and

C. immitis, which are further divided into five well-defined populations (20-22). *C. posadasii* has

a more extensive biogeographic distribution and is divided into three populations, occurring in

Texas/Venezuela, Mexico/South America, and Arizona. The species *C. immitis* is divided into

two populations found in central and southern California, and recently Washington State,

representing a newly discovered third distinct population (23, 24). Representative members of all

populations cause disease in humans and other mammals (20-22). Due to the magnitude of

observed genetic variation and geographic distribution between species, we hypothesized that

metabolomic variation exists. To capture diversity across the volatilome between and within

species, we included a total of twelve isolates from both species, representing four populations,

all of which were isolated from humans (Table 1).

Table 1. *Coccidioides* spp. strains used in this study. All isolates are from human infections.

Species	Strain	Population*	ATCC	NCBI**
C. posadasii	Silveira	AZ	NR-48944	ABAI00000000.2
	B3221	AZ		NA
	B3222	AZ		NA
	RMSCC2343	TX/MEX/SA		SRR3468064
	RMSCC3506	TX/MEX/SA		SRR3468053
	GT-166	TX/MEX/SA		NA
C. immitis	RS	SDMX	NR-48942	AAEC00000000.3
	RMSCC2395	SDMX	NR-48938	NA
	RMSCC3505	SDMX		NA
	RMSCC2006	SJV	NR-48934	NA
	RMSCC2009	SJV		SRR3468015
	RMSCC2010	SJV	NR-48935	NA

120 *Populations are defined as *C. posadasii* collected from Arizona (AZ), *C. posadasii* collected
121 from Texas/Mexico/South America (TX/MEX/SA), *C. immitis* collected from San Diego,
122 California, and Mexico (SDMX), and *C. immitis* collected from San Joaquin Valley, California
123 (SJV), as previously published (25). **Published genotype data, if available (21).

Characteristics of the *Coccidioides* volatilome by species and lifecycle

We cultured each *Coccidioides* isolate in biological triplicate using temperatures and oxygen

concentrations that induce mycelial or spherule growth, but using the same culture medium,

facilitating direct comparisons between the VOCs produced during the two lifecycles. Using

solid-phase microextraction to adsorb VOCs from the headspace of fungal culture filtrates, and

GC×GC–TOFMS to analyze the volatilomes, we detected a total of 353 chromatographic peaks

that were at least two-fold more abundant in a *Coccidioides* culture (n = 72) versus the medium

controls (n = 6) (Table S1). Of the 353 volatiles detected in *Coccidioides* cultures, 28 were

assigned putative names based on mass spectral and chromatographic data, which included 13

compounds previously associated with human and environmental fungal pathogens (26) (Table

2). For the unnamed compounds, we assigned chemical classifications to 45 of them based on a

combination of mass spectral and chromatographic characteristics (Table S1).

The total number of volatiles produced by *C. posadasii* versus *C. immitis* were similar, at 291

versus 309, respectively (Figure 1; Table S2). Within each species, the two lifecycles are quite

divergent in their volatilomes, sharing less than a third of the total volatilome (Figure 1, A and

B). However, within each lifecycle, the two species share many similarities, with more than half

of the VOCs produced by both *C. posadasii* and *C. immitis* (Figure 1, C and D). In aggregate

across the genus, or subdivided by species, the spherule volatilome is larger than the mycelial

volatilome, but this appears to be driven by considerable differences in volatilome sizes observed

in a few isolates (*C. posadasii* B3221, GT-166; *C. immitis* RS; Table S2).

Table 2. Named *Coccidioides* spp. volatiles and their previous reports in other fungal taxa.

VOC	Compound	Functional class	CAS	1	2	3	4	5	6	7	References
				Fungal taxa*							
29	acetonitrile	nitrogen-containing	75-05-8								
97	acetic acid	carboxylic acid/ester	64-19-7	x	x						(27, 28)
147	acetoin	ketone	513-86-0		x						(28)
159	2-methyl-1-butanol	alcohol	137-32-6	x	x		x	x	x	x	(29-33)
195	hexanal	aldehyde	66-25-1	x	x						(28, 29, 34)
196	4-methyl-3-penten-2-one	ketone	141-79-7								
206	N,N-dimethyl-formamide	nitrogen-containing	68-12-2								
239	1-hexanol	alcohol	111-27-3		x						(29)
255	2-hexen-1-ol	alcohol	2305-21-7								
270	cyclohexanone	ketone	108-94-1	x	x	x			x		(31, 35)
299	1-ethyl-4-methyl-benzene	aromatic hydrocarbon	622-96-8								
320	2,5-hexanedione	ketone	110-13-4								
332	2-pentylfuran	heteroaromatic	3777-69-3	x			x			x	(32, 33, 36-39)
354	5-methyl-3-heptanone	ketone	541-85-5								
359	β-pinene	monoterpene	127-91-3	x					x		(14, 17, 31, 34)
364	4,6-dimethyl-2-heptanone	ketone	19549-80-5								
383	limonene	monoterpene	138-86-3	x	x		x		x	x	(14, 17, 29-31, 33, 34, 40-42)
386	1-methyl-3-(1-methylethyl)-benzene	aromatic hydrocarbon	535-77-3								
411	2-chloro-phenol	aromatic alcohol	95-57-8								

				1	2	3	4	5	6	7	
428	2,4,6-trimethlpryidine	nitrogen-containing, aromatic	108-75-8								
435	3-undecene	hydrocarbon	1002-68-2								
456	benzeneacetaldehyde	aromatic aldehyde	122-78-1		x				x		(29, 40)
502	1,3-diethenyl-benzene	aromatic	108-57-6								
545	2-decanone	ketone	693-54-9							x	(33)
554	2-(2-butoxyethoxy)-ethanol	alcohol	112-34-5								
555	decanal	aldehyde	112-31-2	x	x						(29, 34)
820	2-butyl-1-octanol	alcohol	3913-02-8								
955	hexadecane	hydrocarbon	544-76-3	x							(13)

*Fungal taxa: 1 = *Aspergillus* spp.; 2 = *Candida* spp.; 3 = *Cladosporium cladosporoides*; 4 = *Fusarium*
spp.; 5 = *Mucor* spp.; 6 = *Penicillium* spp.; 7 = Other spp., including environmental fungal species,
Tricoderma spp., *Stropharia rugosoannulata*, *Verticillium longisporum*

Figure 1. The numbers of analytes in at least two-fold greater abundance in a *Coccidioides*
culture versus the media controls that are shared and unique among **A**) *C. posadasii* mycelia

(square) vs. spherules (circle); **B**) *C. immitis* mycelia (square) vs. spherules (circle); **C**) mycelia

of *C. posadasii* (red) vs. *C. immitis* (blue); and **D**) spherules of *C. posadasii* (red) vs. *C. immitis*

(blue).

Analyzing the relative abundances of individual analytes, we observed some statistically-

significant differences in VOCs produced during the two lifecycles, but not between the two

species. We performed a Mann-Whitney *U*-test using Benjamini-Hochberg false discovery rate

(FDR) correction comparing all spherule and mycelial VOCs, and identified 43 that were

significantly different in abundance ($p < 0.05$) (Figure 2). Of the 43 volatiles, 32 of them were

higher in abundance in spherule compared to 11 in mycelia, which mirrors the overall difference

in the size of the volatilomes (Figure 1). Among the VOCs detected in higher abundance in one

lifecycle versus another were 1-methyl-3-(1-methylethyl)-benzene and hexanal, which are

associated with mycelia cultures, while 2-(2-butoxyethoxy)-ethanol, cyclohexanone, 2-hexen-1-

ol, and 2,4,6-trimethlpryidine were associated with spherule cultures. There were no VOCs that

were significantly different in relative abundance between *C. posadasii* and *C. immitis*.

Figure 2. Forty-three volatiles significantly different in abundance between lifecycles ($p < 0.05$), expressed as log$_2$ fold change in peak abundance. Maroon and tan represent spherule and mycelia peaks, respectively. Volatiles marked with an asterisks indicate greater statistically-significant differences (* $p < 0.001$, ** $p < 0.0001$). Compound IDs: 195 = hexanal; 255 = 2-hexen-1-ol; 270 = cyclohexanone; 386 = 1-methyl-3-(1-methylethyl)-benzene; 428 = 2,4,6-trimethlpryidine; 554 = 2-(2-butoxyethoxy)-ethanol.

Most (> 70%) of the spherule and mycelial VOCs detected in this study were produced by four

or fewer *Coccidioides* strains in each lifecycle. Of the 272 spherule volatiles that were detected,

only 35 (13%) were detected in at least two-thirds of all spherule cultures (Figure 3A), 12 of

which were also significantly more abundant in spherule versus mycelia cultures. Nineteen of

224 mycelia volatiles (8%) were detected in at least two-thirds of all mycelia samples (Figure

3B), and only two were significantly different between lifecycles (VOC 199 and 428). However,

185   both volatiles were produced in higher relative abundance in spherules. Only two VOCs, 39 and

186   748, were detected in two-thirds of both spherule and mycelia samples. Interestingly, the relative

187   abundance of a VOC was usually consistent across all strains. For example, in every spherule

188   culture in which limonene (VOC 383) was detected, it was at a relative concentration between

189   two and tenfold greater than media (Figure 3A).

Figure 3. Volatiles detected in at least two-thirds of all *Coccidioides* strains in spherule (A) or
mycelial (B) cultures, with VOCs in bold detected in both lifecycles. Open shapes indicate VOCs
that are at least 2-fold greater in relative abundance compared to media blanks, and solid shapes
indicate VOCs that are at least 10-fold greater in relative abundance. Volatiles marked with an
asterisks indicate statistically-significant differences in abundance between lifecycles (* p <
0.05, ** p < 0.001, *** p < 0.0001). Strains are color-coded as *C. immitis* (blue) and *C.
posadasii* (red). The percentages of listed VOCs detected in each strain, and the percentages of
strains producing each VOC are noted at the bottom and right side of each chart, respectively.
Compound IDs: 97 = acetic acid; 239 = 1-hexanol; 255 = 2-hexen-1-ol; 383 = limonene; 428 =
2,4,6,-trimethyl-pyridine; 820 = 2-butyl-1-octanol.

Multivariate analyses of the *Coccidioides* volatilome

Principal components analysis (PCA), using the 78 cultures and media blanks as observations

and 353 *Coccidioides* VOCs as variables, shows that the volatilomes of individual strains and

culture conditions are highly reproducible (Figure S1A), and that they cluster by lifecycle, not by

species (Figure 4). This observation is reinforced when we include only mycelia or spherules in

the PCA, where no separation between species is observed (Figure S1, B and C), or only include

C. immitis or *C. posadasii*, where we still observe clear separation by lifecycle (Figure S1, D and

E). Evaluating these subsets of the data, some interesting variations between strains emerge. The

type strain for *C. immitis* is RS; however, in both mycelial and spherule lifecycles, we observe

that its volatile metabolome is quite unique from the other *C. immitis* strains (Figure S1). *C.*

posadasii also has a metabolic outlier – RMSCC3506 – but only during mycelial growth (Figure

S1, B and E). These outliers cannot be fully explained by the size of the volatilomes as being

abnormally large or small (Table S2).

Figure 4. Principal components analysis (PCA) score plot using 353 VOCs as features, produced
by *C. immitis* (blue) and *C. posadasii* (red) when cultured in conditions that induced spherule
(circle) or mycelial (square) morphologies. Blank media are shown in gray. Fungal cultures and
media blanks were analyzed in triplicate, yielding 72 fungal and 6 blank observations. PCA score
plots with the observations colored by strain are in Figure S1.

Though lifecycle and strain differences in the *Coccidioides* volatilome are observable in the

PCA, less than a quarter of the total variance is captured by the first two PCs. Thus, we also used

hierarchical clustering analysis (HCA) to compare the *Coccidioides* volatilomes (Figure 5). The

HCA reinforces our finding that lifecycle is the most significant contributor to the *Coccidioides*

volatilome, and there are not global similarities in the volatilomes within each species, or within

populations of the species. There are two main clusters of VOCs driving the separation of the

mycelia and spherule lifecycles in the HCA. Cluster 1 includes 56 VOCs, which are generally

present in a higher abundance in mycelia samples compared to spherule samples, five of which

are significantly different between lifecycles ($p < 0.05$ with Benjamini-Hochberg FDR

correction; Table S1). In Cluster 1, seven compounds are identified: 3-undecene, 1-ethyl-4-

methyl-benzene, 1-methyl-3-(1-methylethyl)-benzene, 2-butyl,1-octanol, decanal, limonene, and

β-pinene. As in the PCA, we find that *C. immitis* RS and *C. posadasii* RMSCC3506 are

clustering separately when grown as mycelia, partially driven by low abundances of VOCs from

Cluster 1. Cluster 2 includes 16 VOCs that are present in spherule samples while generally

absent or at a lower abundance in mycelia samples, and all of which are significantly different

between lifecycles ($p < 0.05$ with Benjamini-Hochberg FDR correction). Cyclohexanone and

2,4,6-trimethlpryidine are two VOCs in this cluster that we were able to identify.

Figure 5. Hierarchical clustering analysis (HCA) of 72 fungal cultures and 6 media blanks (columns) based on the relative abundance of 353 volatiles (rows). Clustering of fungi and blank samples is using Pearson correlations, and clustering of volatiles is using Euclidean distance, both with average linkage. Samples are color-coded by strain, population, species, and lifecycle, as labeled in the legend; media blanks are in gray.

DISCUSSION

The genus *Coccidioides* is divided into two closely related and putatively allopatric species, with a strong phylogeographic signal and population substructure within each species (19). However, we find that the character of the *Coccidioides* volatilome is determined by lifecycle rather than species. Within each species, the two lifecycles have a relatively small overlap in their shared volatilome, with 27% and 31% shared for *C. posadasii* and *C. immitis,* respectively (Figure 1). While there were no volatiles that were significantly different in relative abundance between *C. posadasii* and *C. immitis*, we observed 43 statistically-significant differences in the VOCs produced during the two lifecycles (Figure 2). This global difference between lifecycles is the primary driver of separation we observed in multivariate analyses using PCA (Figure 4) and HCA (Figure 5). These findings are in line with the large-scale transcriptional changes that occur when *Coccidioides* spp. transitions from mycelial to spherule growth; between 20% and 40% of the *Coccidioides* genes are differentially regulated during the shift between the environmental and parasitic lifecycles (43-46). It has also been shown that the proteomes of the two lifecycles are distinct, with statistically-significant differences between mycelia and spherule lifecycles (47). In contrast to the significant differences in the volatilomes between lifecycles, we observed no uniform differences between the volatilomes of *C. posadasii* and *C. immitis*. There is a high degree of overlap (56 – 57%) between the species' volatilomes when comparing the same lifecycle (Figure 1). This similarity is also visible in the PCA (Figures 4 and S1) and HCA (Figure 5), as the volatilomes do not cluster by species even when we control for lifecycle.

Global similarities between *C. posadasii* and *C. immitis* have also been demonstrated at the

protein level (47, 48).

The lack of significant differences between the *C. posadasii* and *C. immitis* volatilomes is due, in

part, to large differences observed between strains of the same species; the volatilome highlights

some unique aspects of a few of the individual *Coccidioides* strains that we analyzed. For

example, RS is the type strain for *C. immitis*; however, it appears to be a metabolic outlier during

both lifecycles (Figure S1), but especially during mycelial growth (Figure 5). Additionally, the

mycelia lifecycle of *C. posadasii* RMSCC3506 appears to be a metabolic outlier compared to the

other strains grown as mycelia (Figures S1 and 5). These mycelia outliers appear to be driven, at

least in part, by the lack of volatiles that make up Cluster 1 in the HCA (Figure 5). None of the

56 VOCs found in Cluster 1, which are more abundant in mycelia compared to spherule cultures,

are detected in RMSCC3506 cultures, and only two are detected in RS mycelia cultures. These

two strains are also lacking VOCs 39 and 748, which were detected in the majority of strains for

both lifecycles, but absent from both lifecycles of RS and mycelia cultures of RMSCC3506

(Figure 3). Additionally, none of the 11 VOCs significantly more abundant in mycelia over

spherule cultures (Figure 2 and Table S1) are detected in RMSCC3506, and only two are

detected in RS. Beyond contributing to high levels of volatilome variance in *Coccidioides*, the

significance of the strain level differences relative to fungal biology or infection are not known.

Variation in virulence in murine models of coccidioidomycosis among strains has been observed,

but has not been tested in the context of species or with a mechanistic hypothesis to test (49). In

future studies of mouse model and human infections we plan to investigate correlations between

the *Coccidioides* volatilome and virulence and infection outcomes.

It should be noted that although the spherule and mycelia media had the same composition, we

detected different VOCs in the headspace of the blanks (Table S1, Figures 4 and 5). We interpret

these differences as the influence of the cultures on the blanks, rather than the influence of the

blank media on the cultures. Because the media blanks were incubated and processed in parallel

with their respective samples, we posit that the blank media absorbed volatiles from the culture

environment (e.g., from fungal spherule or mycelial cultures in shared incubators), which

introduced differences in their volatilomes. An analysis of fresh blank media (not incubated with

the cultures) would be required to test this hypothesis. Our data indicate that the spherule media

absorbed a greater abundance of compounds compared to the mycelia media (Table S1), which

may be due to the spherule lifecycle producing greater numbers and/or abundances of individual

compounds. Therefore, it is possible there are additional significant spherule volatiles that were

not identified within this study, since a VOC was defined as "detected" based on its relative

abundance versus media blanks. Future *in vitro* work needs to be mindful of volatile absorption

by the cultures and blanks within a shared space, such as an incubator.

The results from this study highlight two crucial factors that need to be considered in the

development and translation of volatilomics (and other functional genomics data) into

biomarkers. First, there can be a significant amount of intra-species variation, such that the

volatilome of a single strain is not representative of the species as a whole (17, 27, 50, 51).

Therefore, the analysis of multiple strains should be performed to identify a core volatilome, and

the more genetically and phenotypically diverse the species, the more strains will need to be

analyzed to determine the consensus set of volatiles produced by the majority of them. Second,

our data show that the growth phase of the organism has a strong influence on the volatilome,

and therefore using *in vitro* culture conditions that can most closely replicate the *in vivo*

environment and microbial growth phases may increase the likelihood of putative biomarker

translation from bench to bedside. In addition to controlling the growth phase of dimorphic

organisms, macronutrient, micronutrient, and oxygen availability should all be considered in the

development of *in vitro* model systems that replicate *in vivo* physiology of the pathogen (14, 17,

27, 30, 33, 36, 52, 53). Our next step in developing a Valley fever breath test is to translate *in*

vitro biomarkers for use with an *in vivo* mouse model. We observed 35 VOCs present in at least

67% of all spherule strains (Figure 3); as this is the parasitic lifecycle found within the host, we

hypothesize that the most highly conserved spherule VOCs have the greatest probability of

translating to Valley fever breath biomarkers.

MATERIALS AND METHODS

Fungal Isolates and Growth Conditions

Isolates: The *Coccidioides* isolates used in the study were obtained from human patients and are

listed in Table 1. All *Coccidioides* isolates were grown under BSL-3 containment, using

conditions that induce mycelial or spherule growth.

For mycelial growth, a 50 ml vented falcon tube containing 10 ml of RPMI media (filter

sterilized RPMI 1640, 10% fetal bovine serum) was inoculated with a 1 cm × 1 cm 2xGYE agar

plug for each strain. These plates were inoculated using 100 µl of glycerol stock, spread across

the plate, and cultured for 30°C for two weeks. Control RPMI media was inoculated with a plug

from sterile 2xGYE agar media. Each sample, including media control, was prepared in

triplicate. Cultures were grown on a shaking incubator at 150 rpm, 30°C for 96 h. For spherule

cultures, a 50 ml vented falcon tube containing 10 ml of RPMI media was inoculated to a final

concentration of 1.0×10^5 arthroconidia/ml in 1x phosphate-buffered saline (PBS).

Arthroconidia were grown and harvested as previously described (54). Strains RMSCC2343 and

RMSCC3505 did not produce enough conidia to achieve 1.0×10^5 arthroconidia/ml, and were

inoculated at 7.0×10^4 and 4.0×10^4 arthroconidia/ml, respectively. Control media was

inoculated with 1 ml of sterile 1xPBS. Cultures were grown on a shaking incubator at 150 rpm,

at 39°C in 10% CO_2 for 96 h. Mycelial and spherule cultures were spun at $12,000 \times g$ at 4°C for

10 min to pellet the cells. The supernatant was removed and place in a Nanosep MF Centrifugal

Devices with Bio-Inert® Membrane 0.2 μm spin filter and centrifuged at 3,200 x g for 4 min.

The filtrate was stored at −80°C until volatile metabolomics analysis.

To ensure sterility of the filtrates for metabolomics analyses outside of a BSL-3 containment

facility, 10% of all sample filtrates were plated on 2xGYE and incubated at 30°C for 96 h to

ensure complete removal of viable pathogen particles. No growth was observed in any replicate.

Volatile metabolomics analysis by SPME-GC×GC–TOFMS

The *Coccidioides* spp. culture filtrates and media blanks were allowed to thaw at 4°C overnight,

and then 2 ml were transferred and sealed into sterilized 10 ml GC headspace vials with

PTFE/silicone septum screw caps. All samples were stored for up to 12 d at 4°C until analyzed.

Samples were randomized for analysis. Volatile metabolites sampling was performed by solid-

phase microextraction (SPME) using a Gerstel® Multipurpose Sampler directed by

Maestro® software. Volatile metabolite analysis was performed by two-dimensional gas

chromatography−time-of-flight mass spectrometry (GC×GC–TOFMS) using a LECO Pegasus

4D and Agilent 7890 GC (St. Joseph, MI). Chromatographic, mass spectrometric, and peak

detection parameters are provided in Table S3 (GC parameters). An external alkane standards

mixture (C_8 – C_{20}; Sigma-Aldrich, St. Louis, MO) was sampled multiple times for calculating

retention indices (RI). The injection, chromatographic, and mass spectrometric methods for

analyzing the alkane standards were the same as for the samples.

Processing and analysis of chromatographic data

Data collection, processing, and alignment were performed using ChromaTOF software version

4.71 with the Statistical Compare package (Leco Corp.), using the parameters listed in Table S3

(GC parameters).

Peaks were assigned a putative identification based on mass spectral similarity and RI data, and

the confidence of those identifications are indicated by assigning levels 1 – 4 (1 highest) (55).

Peaks with a level 1 ID were identified based on mass spectral and retention index matches with

external standards. Peaks with a level 2 ID were identified based on ≥ 800 mass spectral match

by a forward search of the NIST 2011 library and RI that are consistent with the midpolar Rxi-

624Sil stationary phase, as previously described (50), but using an RI range of 0 – 43%

(empirically determined by comparing the Rxi-624Sil RIs for Grob mix standards to published

polar and non-polar values). Level 1, 2, and 3 compounds were assigned to chemical functional

groups based upon characteristic mass spectral fragmentation patterns and second dimension

retention times, as previously described (51). Level 4 compounds have mass spectral matches <

600 or retention indices that do not match previously published values, and are reported as

unknowns.

Data post processing and statistical analyses

The data post processing steps are depicted in Figure S2. Before statistical analyses, compounds

eluting prior to 358 s (acetone retention time) and siloxanes (*i.e.,* chromatographic artifacts) were

removed from the peak table. Peaks that were present in only one of the three biological

replicates were imputed to zero for that sample, while missing values for peaks that were present

in two out of three biological replicates were imputed to half of the minimum value across all

biological replicates. The relative abundances of compounds across chromatograms were

normalized using probabilistic quotient normalization (PQN) (56) in R version 3.4.3. The data

were $\log_{10}$ transformed, and intraclass correlation coefficients (ICCs) were calculated using R

ICC package version 2.3.0, and peaks with an ICC < 0.75 were not further processed. Analytes

were retained for further analysis if they were at least two-fold more abundant in any

Coccidioides culture compared to media controls, and were considered to have been detected in

that culture. Principal component analysis was performed using R *factoextra* package version

1.0.5 with the biological replicates as observations and the absolute peak intensities (mean-

centered and scaled to unit variance) as variables. The relatedness of samples based on their

volatile metabolomes were assessed using hierarchical clustering analysis on the Pearson's

correlation between isolates and Euclidean distance between volatiles using R *pheatmap* package

version 1.0.12. Geometric means of the biological replicates were calculated and used to

determine the statistical difference in abundance between lifecycles or species using a Mann-

Whitney *U*-test and Benjamini and Hochberg false discovery rate correction with $\alpha = 0.05$, using

R *stats* package version 3.5.3. The variation in abundance of volatiles significantly different

between lifecycle was calculated by dividing mean mycelia peak abundance by mean spherule

peak abundance.

Data availability

Metabolomic data (chemical feature peak areas and retention time information)

included in this study are available at the NIH Common Fund's National Metabolomics Data

Repository (NMDR) website, the Metabolomics Workbench, at

www.metabolomicsworkbench.org, where it has been assigned project ID PR000### and study

ID ST00### (https://doi.org/####).

CONCLUSION

The *Coccidioides* volatilome is strongly influenced by the environmental versus parasitic

lifecycles, while the two species, *C. posadasii* and *C. immitis*, are indistinguishable by their

volatile profiles, in part due to high strain to strain variability within the species. We identified

35 VOCs produced by the majority of the *Coccidioides* strains when grown as spherules, the

parasitic form of the fungus found in Valley fever lung infections. Our results show that as future

efforts are made to develop biomarkers for *Coccidioides* and other mycoses caused by dimorphic

fungi, it is vitally important to control for fungal lifecycle and sample multiple strains of the

pathogen to identify volatiles that are more highly conserved within the infectious genus or

species.

ACKNOWLEDGEMENTS

Funding for this work was provided by the Arizona Biomedical Research Commission (ABRC)

award ADHS18-198861 (HDB). We thank John Galgiani and George Thompson who provided

Coccidioides clinical isolates to BMB.

We declare that the research was conducted in the absence of any commercial or financial

relationships that could be construed as a potential conflict of interest.

REFERENCES

1. Chiller T. 2019. Overview of endemic mycoses, NIAID, Rockville, MD.
2. Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, Orbach MJ, Galgiani JN. 2013. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. Clin Microbiol Rev 26:505-525.
3. Wilson L, Ting J, Lin H, Shah R, MacLean M, Peterson MW, Stockamp N, Libke R, Brown P. 2019. The rise of Valley fever: Prevalence and cost burden of coccidioidomycosis infection in California. Int J Environ Res Public Health 16.
4. Odio CD, Marciano BE, Galgiani JN, Holland SM. 2017. Risk factors for disseminated coccidioidomycosis, United States. Emerg Infect Dis 23:308-311.
5. Grys TE, Brighton A, Chang Y-H, Liesman R, Bolster LaSalle C, Blair JE. 2018. Comparison of two FDA-cleared EIA assays for the detection of *Coccidioides* antibodies against a composite clinical standard. Med Mycol 57:595-600.
6. Kassis C, Durkin M, Holbrook E, Myers R, Wheat L. 2020. Advances in diagnosis of progressive pulmonary and disseminated coccidioidomycosis. Clin Infect Dis doi:10.1093/cid/ciaa188.
7. Singh VR, Smith DK, Lawerence J, Kelly PC, Thomas AR, Spitz B, Sarosi GA. 1996. Coccidioidomycosis in patients infected with human immunodeficiency virus: Review of 91 cases at a single institution. Clin Infect Dis 23:563-8.
8. Muñoz-Hernández B, Palma-Cortés G, Cabello-Gutiérrez C, Martínez-Rivera MA. 2014. Parasitic polymorphism of *Coccidioides* spp. BMC Infect Dis 14:213.
9. Ampel NM. 2010. The diagnosis of coccidioidomycosis. F1000 Med Rep 2:2.
10. Galgiani JN, Grace GM, Lundergan LL. 1991. New serologic tests for early detection of coccidioidomycosis. J Infect Dis 163:671-674.
11. Davis CE, Hill JE, Frank M, McCartney MM, Schivo M, Bean HD. 2020. Breath analysis for respiratory infections, p 335-347. *In* Beauchamp JD, Davis CE, Pleil JD (ed), Breathborne biomarkers and the human volatilome, 2nd ed. Elsevier, Amsterdam, Netherlands.
12. Chippendale TWE, Gilchrist FJ, Španěl P, Alcock A, Lenney W, Smith D. 2014. Quantification by SIFT-MS of volatile compounds emitted by *in vitro* cultures of *S.*

aureus, *S. pneumoniae* and *H. influenzae* isolated from patients with respiratory diseases.
Anal Methods 6:2460-2472.

13.   Neerincx AH, Geurts BP, Habets MFJ, Booij JA, Van Loon J, Jansen JJ, Buydens LMC,
van Ingen J, Mouton JW, Harren FJM. 2016. Identification of *Pseudomonas aeruginosa*
and *Aspergillus fumigatus* mono-and co-cultures based on volatile biomarker
combinations. J Breath Res 10:016002.

14.   Heddergott C, Calvo AM, Latge JP. 2014. The volatome of *Aspergillus fumigatus*.
Eukaryot Cell 13:1014-1025.

15.   Rees CA, Stefanuto P-H, Beattie SR, Bultman KM, Cramer RA, Hill JE. 2017. Sniffing
out the hypoxia volatile metabolic signature of *Aspergillus fumigatus*. J Breath Res 11.

16.   Dickschat JS. 2017. Fungal volatiles – a survey from edible mushrooms to moulds. Nat
Prod Rep 34:310-328.

17.   Koo S, Thomas HR, Daniels SD, Lynch RC, Fortier SM, Shea MM, Rearden P, Comolli
JC, Baden LR, Marty FM. 2014. A breath fungal secondary metabolite signature to
diagnose invasive aspergillosis. Clin Infect Dis 59:1733-1740.

18.   Fisher MC, Koenig GL, White TJ, San-Blas G, Negroni R, Alvarez IG, Wanke B, Taylor
JW. 2001. Biogeographic range expansion into South America by *Coccidioides immitis*
mirrors New World patterns of human migration. Proc Natl Acad Sci U S A 98:4558-
4562.

19.   Fisher MC, Koenig GL, White TJ, Taylor JW. 2002. Molecular and phenotypic
description of *Coccidioides posadasii* sp. nov., previously recognized as the non-
California population of *Coccidioides immitis*. Mycologia 94:73-84.

20.   Engelthaler DM, Roe CC, Hepp CM, Teixeira M, Driebe EM, Schupp JM, Gade L,
Waddell V, Komatsu K, Arathoon E, Logemann H, Thompson GR, III, Chiller T, Barker
B, Keim P, Litvintseva AP. 2016. Local population structure and patterns of western
hemisphere dispersal for *Coccidioides* spp., the fungal cause of Valley fever. mBio
7:e00550-16.

21.   Teixeira MM, Barker BM. 2016. Use of population genetics to assess the ecology,
evolution, and population structure of *Coccidioides*. Emerg Infect Dis 22:1022-1030.

22.   Teixeira MM, Alvarado P, Roe CC, Thompson GR, III, Patané JSL, Sahl JW, Keim P,
Galgiani JN, Litvintseva AP, Matute DR, Barker BM. 2019. Population structure and
genetic diversity among isolates of *Coccidioides posadasii* in Venezuela and surrounding
regions. mBio 10.

23.   Marsden-Haug N, Hill H, Litvintseva AP, Engelthaler DM, Driebe EM, Roe CC, Ralston
C, Hurst S, Goldoft M, Gade L, Wohrle R, Thompson GR, III, Brandt ME, Chiller T.
2014. *Coccidioides immitis* identified in soil outside of its known range - Washington,
2013. MMWR Morb Mortal Wkly Rep 63:450.

24.   Litvintseva AP, Marsden-Haug N, Hurst S, Hill H, Gade L, Driebe EM, Ralston C, Roe
C, Barker BM, Goldoft M, Keim P, Wohrle R, Thompson GR, III, Engelthaler DM,
Brandt ME, Chiller T. 2015. Valley fever: Finding new places for an old disease:
Coccidioides immitis found in Washington state soil associated with recent human
infection. Clin Infect Dis 60:e1-e3.

25.   Barker BM, Tabor JA, Shubitz LF, Perrill R, Orbach MJ. 2012. Detection and
phylogenetic analysis of *Coccidioides posadasii* in Arizona soil samples. Fungal Ecol
5:163-176.

26.   Hérivaux A, Gonçalves SM, Carvalho A, Cunha C. 2020. Microbiota-derived metabolites
512   as diagnostic markers for respiratory fungal infections. J Pharm Biomed Anal
513   189:113473.

514   27.   Bazemore RA, Feng J, Cseke L, Podila GK. 2012. Biomedically important pathogenic
515   fungi detection with volatile biomarkers. J Breath Res 6:016002.

516   28.   Filipiak W, Beer R, Sponring A, Filipiak A, Ager C, Schiefecker A, Lanthaler S, Helbok
517   R, Nagl M, Troppmair J. 2015. Breath analysis for *in vivo* detection of pathogens related
518   to ventilator-associated pneumonia in intensive care patients: A prospective pilot study. J
519   Breath Res 9:016004.

520   29.   Costa CP, Bezerra AR, Almeida A, Rocha SM. 2020. *Candida* species (volatile)
521   metabotyping through advanced comprehensive two-dimensional gas chromatography.
522   Microorganisms 8:1911.

523   30.   Fiedler K, Schütz E, Geh S. 2001. Detection of microbial volatile organic compounds
524   (MVOCs) produced by moulds on various materials. Int J Hyg Environ Health 204:111-
525   121.

526   31.   Matysik S, Herbarth O, Mueller A. 2009. Determination of microbial volatile organic
527   compounds (MVOCs) by passive sampling onto charcoal sorbents. Chemosphere 76:114-
528   119.

529   32.   Müller A, Faubert P, Hagen M, zu Castell W, Polle A, Schnitzler J-P, Rosenkranz M.
530   2013. Volatile profiles of fungi – chemotyping of species and ecological functions.
531   Fungal Genet Biol 54:25-33.

532   33.   Nemčovič M, Jakubíková L, Víden I, Farkaš V. 2008. Induction of conidiation by
533   endogenous volatile compounds in *Trichoderma* spp. FEMS Microbiol Lett 284:231-236.

534   34.   Polizzi V, Adams A, Malysheva SV, De Saeger S, Van Peteghem C, Moretti A, Picco
535   AM, De Kimpe N. 2012. Identification of volatile markers for indoor fungal growth and
536   chemotaxonomic classification of *Aspergillus* species. Fungal Biol 116:941-953.

537   35.   Perl T, Jünger M, Vautz W, Nolte J, Kuhns M, Borg-von Zepelin M, Quintel M. 2011.
538   Detection of characteristic metabolites of *Aspergillus fumigatus* and *Candida* species
539   using ion mobility spectrometry – metabolic profiling by volatile organic compounds.
540   Mycoses 54:e828-e837.

541   36.   Gao P, Korley F, Martin J, Chen BT. 2002. Determination of unique microbial volatile
542   organic compounds produced by five *Aspergillus* species commonly found in problem
543   buildings. AIHA J (Fairfax, Va) 63:135-140.

544   37.   Syhre M, Scotter JM, Chambers ST. 2008. Investigation into the production of 2-
545   pentylfuran by *Aspergillus fumigatus* and other respiratory pathogens *in vitro* and human
546   breath samples. Med Mycol 46:209-215.

547   38.   Chambers ST, Bhandari S, Scott-Thomas A, Syhre M. 2011. Novel diagnostics: Progress
548   toward a breath test for invasive *Aspergillus fumigatus*. Med Mycol 49:S54-S61.

549   39.   Chambers ST, Syhre M, Murdoch DR, McCartin F, Epton MJ. 2009. Detection of 2-
550   pentylfuran in the breath of patients with *Aspergillus fumigatus*. Med Mycol 47:468-476.

551   40.   Jeleń HH. 2003. Use of solid phase microextraction (SPME) for profiling fungal volatile
552   metabolites. Lett Appl Microbiol 36:263-267.

553   41.   Acharige MJT, Koshy S, Ismail N, Aloum O, Jazaerly M, Astudillo CL, Koo S. 2018.
554   Breath-based diagnosis of fungal infections. J Breath Res 12:027108.

42.   Ahmed WM, Geranios P, White IR, Lawal O, Nijsen TM, Bromley MJ, Goodacre R,
Read ND, Fowler SJ. 2018. Development of an adaptable headspace sampling method for
metabolic profiling of the fungal volatome. Analyst 143:4155-4162.
43.   Mead HL, Roe CC, Higgins Keppler EA, Caballero Van Dyke MC, Laux KL, Funke AL,
Miller KJ, Bean HD, Sahl JW, Barker BM. 2020. Defining critical genes during spherule
remodeling and endospore development in the fungal pathogen, *Coccidioides posadasii*.
Front Genet 11.
44.   Caballero Van Dyke MC, Teixeira MM, Barker BM. 2019. Fantastic yeasts and where to
find them: The hidden diversity of dimorphic fungal pathogens. Curr Opin Microbiol
52:55-63.
45.   Viriyakosol S, Singhania A, Fierer J, Goldberg J, Kirkland TN, Woelk CH. 2013. Gene
expression in human fungal pathogen *Coccidioides immitis* changes as arthroconidia
differentiate into spherules and mature. BMC Microbiol 13:121.
46.   Whiston E, Wise HZ, Sharpton TJ, Jui G, Cole GT, Taylor JW. 2012. Comparative
transcriptomics of the saprobic and parasitic growth phases in *Coccidioides* spp. PLoS
One 7:e41034.
47.   Mitchell NM, Grys TE, Lake DF. 2019. Carbo-loading in *Coccidioides* spp.: A
quantitative analysis of CAZyme abundance and resulting glycan populations.
Glycobiology 30:186-196.
48.   Mitchell NM, Sherrard AL, Dasari S, Magee DM, Grys TE, Lake DF. 2018.
Proteogenomic re-annotation of *Coccidioides posadasii* strain Silveira. Proteomics
18:1700173.
49.   Friedman L, Smith CE, Roessler WG, Berman EJ. 1956. The yirulence and infectivity of
twenty-seven strains of *Coccidioides immitis*. Am J Hyg 64:198-210.
50.   Bean HD, Rees CA, Hill JE. 2016. Comparative analysis of the volatile metabolomes of
Pseudomonas aeruginosa clinical isolates. J Breath Res 10:047102.
51.   Davis TJ, Karanjia AV, Bhebhe CN, West SB, Richardson M, Bean HD. 2020.
Pseudomonas aeruginosa volatilome characteristics and adaptations in chronic cystic
fibrosis lung infections. mSphere 5:e00843-20.
52.   Koehler T, Ackermann I, Brecht D, Uteschil F, Wingender J, Telgheder U, Schmitz OJ.
2020. Analysis of volatile metabolites from *in vitro* biofilms of *Pseudomonas aeruginosa*
with thin-film microextraction by thermal desorption gas chromatography-mass
spectrometry. Anal Bioanal Chem 412:2881-2892.
53.   Jenkins CL, Bean HD. 2020. Dependence of the staphylococcal volatilome composition
on microbial nutrition. Metabolites 10.
54.   Mead HL, Teixeira MdM, Galgiani JN, Barker BM. 2019. Characterizing *in vitro*
spherule morphogenesis of multiple strains of both species of *Coccidioides*. Med Mycol
57:478-488.
55.   Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TW, Fiehn O,
Goodacre R, Griffin JL, Hankemeier T, Hardy N, Harnly J, Higashi R, Kopka J, Lane
AN, Lindon JC, Marriott P, Nicholls AW, Reily MD, Thaden JJ, Viant MR. 2007.
Proposed minimum reporting standards for chemical analysis Chemical Analysis
Working Group (CAWG) Metabolomics Standards Initiative (MSI). Metabolomics
3:211-221.

56.   Dieterle F, Ross A, Schlotterbeck G, Senn H. 2006. Probabilistic quotient normalization
600   as robust method to account for dilution of complex biological mixtures. Application in
601   ^{1}H NMR metabonomics. Anal Chem 78:4281-4290.